Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
9.73
+0.08 (0.83%)
At close: Nov 18, 2025, 4:00 PM EST
9.80
+0.07 (0.72%)
After-hours: Nov 18, 2025, 4:07 PM EST
Fulcrum Therapeutics Revenue
In the year 2024, Fulcrum Therapeutics had annual revenue of $80.00M with 2,752.05% growth.
Revenue (ttm)
$80.00M
Revenue Growth
+2,752.05%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
45
Market Cap
530.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 80.00M | 77.20M | 2,752.05% |
| Dec 31, 2023 | 2.81M | -3.54M | -55.77% |
| Dec 31, 2022 | 6.34M | -12.82M | -66.90% |
| Dec 31, 2021 | 19.16M | 10.34M | 117.19% |
| Dec 31, 2020 | 8.82M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
FULC News
- 11 days ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - GlobeNewsWire
- 20 days ago - Fulcrum Therapeutics, Inc. (FULC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 - GlobeNewsWire
- 27 days ago - Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET - GlobeNewsWire
- 3 months ago - Fulcrum Therapeutics to Present at Upcoming Investor Meetings - GlobeNewsWire
- 4 months ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 - GlobeNewsWire
- 4 months ago - Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire